Folotyn for Non-Hodgkin's Lymphoma Jacksonville FL

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Alan Roy Marks
(904) 493-5100
1235 San Marco Blvd
Jacksonville, FL
Specialty
Hematology / Oncology

Data Provided by:
Rizwan D Nurani
(904) 636-6911
5742 Booth Rd
Jacksonville, FL
Specialty
Radiation Oncology

Data Provided by:
Alan Roy Marks, MD
(904) 493-5100
1235 San Marco Blvd Ste 3
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Libre De Bruxelles, Fac De Med Et De Pharm, Bruxelles,
Graduation Year: 1975

Data Provided by:
Suneel L Mahajan
(904) 739-7779
5742 Booth Rd
Jacksonville, FL
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Manisha Makker Bansal
(904) 390-3600
807 Childrens Way
Jacksonville, FL
Specialty
Pediatric Hematology-Oncology

Data Provided by:
Cynthia A Gauger
(904) 390-3789
807 Childrens Way
Jacksonville, FL
Specialty
Pediatric Hematology-Oncology

Data Provided by:
Paul A Pitel
(904) 390-3600
807 Childrens Way
Jacksonville, FL
Specialty
Pediatric Hematology-Oncology

Data Provided by:
Karl H S Smith, MD
(904) 396-0800
820 Prudential Dr Ste 1605
Jacksonville, FL
Specialties
Oncology (Cancer), Gynecological Oncology, Gynecology
Gender
Male
Education
Medical School: Northwestern Univ Med Sch, Chicago Il 60611
Graduation Year: 1972
Hospital
Hospital: Baptist Med Ctr, Jacksonville, Fl
Group Practice: North FL Gynocologic Spec

Data Provided by:
Yousif Abubak, MD
(904) 739-7779
5742 Booth Rd
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Scott Mark Bradfield, MD
807 Childrens Way
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of South Fl Coll Of Med, Tampa Fl 33612
Graduation Year: 1997

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Mailing Address:
Jacksonville Magazine
1261 King St.
Jacksonville, FL 32204
TEL: (904) 389-3622
FAX: (904) 389-3628
E-mail: mail@jacksonvillemag.com